NTRK1 and cancer: Therefore, we hypothesized that disruption of the PDGF-AA/PDGFR-α signaling between OSCC cells and MSCs with the receptor tyrosine kinase inhibitor crenolanib, may restore cancer cell sensitivity to cisplatin.